Lineage Cell Therapeutics, Inc. - FORM 10-K - EX-32 - EXHIBIT 32

Attached files

file	filename
EX-31 - EXHIBIT 31 - Lineage Cell Therapeutics, Inc.	ex31.htm
EX-23.1 - EXHIBIT 23.1 - Lineage Cell Therapeutics, Inc.	ex23_1.htm
EX-21.1 - EXHIBIT 21.1 - Lineage Cell Therapeutics, Inc.	ex21_1.htm
EX-10.39 - EXHIBIT 10.39 - Lineage Cell Therapeutics, Inc.	ex10_39.htm
EX-10.38 - EXHIBIT 10.38 - Lineage Cell Therapeutics, Inc.	ex10_38.htm
10-K - BIOTIME, INC 10-K 12-31-2016 - Lineage Cell Therapeutics, Inc.	form10k.htm

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of BioTime, Inc. (the “Company”) for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Michael D. West, Co-Chief Executive Officer, Aditya Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 16, 2017

	/s/Michael D. West
	Michael D. West Ph.D.
	Co-Chief Executive Officer

	/s/Aditya Mohanty
	Aditya Mohanty
	Co-Chief Executive Officer

	/s/Russell Skibsted
	Russell Skibsted
	Chief Financial Officer

Attached files

Lineage Cell Therapeutics, Inc. Reports

Also read